Prestwick Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
29
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$100M
Prestwick Pharmaceuticals General Information
Description
Developer of small molecule drugs for chronic diseases of the central nervous system (CNS). The company focuses on restless legs syndrome, schizophrenia, autism, Alzheimer's and sleep apnea ailments.
Contact Information
Website
www.prestwickpharma.comCorporate Office
- 1825 K Street Northwest
- Suite 1475
- Washington, DC 20006
- United States
Corporate Office
- 1825 K Street Northwest
- Suite 1475
- Washington, DC 20006
- United States
Prestwick Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 17-Sep-2008 | $100M | Completed | Clinical Trials - Phase 3 | ||
| 7. Debt - General | 02-Aug-2007 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series C1) | 13-Apr-2007 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC (Series C) | 23-Aug-2006 | Completed | Startup | |||
| 4. IPO | 20-Dec-2005 | Cancelled | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series B) | 14-Dec-2004 | Completed | Startup | |||
| 2. Early Stage VC (Series A2) | 19-Jun-2003 | $13M | $23.1M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 10-Mar-2003 | $10.1M | $10.1M | Completed | Startup |
Prestwick Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series B | ||||||||
| Series A2 | 13,030,570 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 13.88% |
| Series A1 | 10,065,999 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 10.73% |
Prestwick Pharmaceuticals Patents
Prestwick Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-0807094-D0 | 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension | Active | 14-Sep-2005 | ||
| GB-2445888-A | 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension | Active | 14-Sep-2005 | ||
| WO-2007031737-A1 | 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension | Inactive | 14-Sep-2005 | ||
| GB-0518763-D0 | Treatment of hypertension | Inactive | 14-Sep-2005 | ||
| GB-2445888-B | Treatment of hypertension | Inactive | 14-Sep-2005 | A61K31/451 |
Prestwick Pharmaceuticals Signals
Prestwick Pharmaceuticals Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| CNF Investments | PE/Buyout | Minority | ||
| Omega Funds | Venture Capital | Minority | ||
| Pequot Ventures | Venture Capital | Minority | ||
| Scale Venture Partners | Venture Capital | Minority |
Prestwick Pharmaceuticals FAQs
-
When was Prestwick Pharmaceuticals founded?
Prestwick Pharmaceuticals was founded in 2002.
-
Where is Prestwick Pharmaceuticals headquartered?
Prestwick Pharmaceuticals is headquartered in Washington, DC.
-
What is the size of Prestwick Pharmaceuticals?
Prestwick Pharmaceuticals has 29 total employees.
-
What industry is Prestwick Pharmaceuticals in?
Prestwick Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Prestwick Pharmaceuticals a private or public company?
Prestwick Pharmaceuticals is a Private company.
-
What is the current valuation of Prestwick Pharmaceuticals?
The current valuation of Prestwick Pharmaceuticals is .
-
What is Prestwick Pharmaceuticals’s current revenue?
The current revenue for Prestwick Pharmaceuticals is .
-
How much funding has Prestwick Pharmaceuticals raised over time?
Prestwick Pharmaceuticals has raised $103M.
-
Who are Prestwick Pharmaceuticals’s investors?
Atlas Venture, CNF Investments, Omega Funds, Pequot Ventures, and Scale Venture Partners are 5 of 8 investors who have invested in Prestwick Pharmaceuticals.
-
When was Prestwick Pharmaceuticals acquired?
Prestwick Pharmaceuticals was acquired on 17-Sep-2008.
-
Who acquired Prestwick Pharmaceuticals?
Prestwick Pharmaceuticals was acquired by Biovail.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process